Rigel Pharmaceuticals Inc (RIGL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $837.18M
Last updated: Nov 17, 2026 at 11:06 AM ET
Rigel Pharmaceuticals Inc (RIGL) Financials: Revenue, Profit and Cash Flow
Rigel Pharmaceuticals reported revenue of $294.28M for the fiscal year ended Dec 31, 2025, up 64.1% from the year before. That year, net income was $367.02M with a net margin of 124.7%, operating cash flow was $75.66M and free cash flow was $75.66M. The quarter ended Sep 30, 2026 had revenue of $80.89M and net income of $13.19M.
Revenue and Margins
The operating margin was 42.6% in the fiscal year ended Dec 2025, the highest of the 6 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $20.38M, a compound annual rate of 34.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $294.28M | +64.1% | 93.3% | 42.6% | 124.7% |
| Dec 2024 | $179.28M | +53.4% | 89.6% | 13.5% | 9.8% |
| Dec 2023 | $116.88M | -2.8% | 93.9% | -17.5% | -21.5% |
| Dec 2022 | $120.24M | -19.4% | 98.5% | -46.2% | -48.7% |
| Dec 2021 | $149.24M | +37.4% | 99.3% | -8.4% | -12.0% |
| Dec 2020 | $108.62M | +83.2% | 99.2% | -26.7% | -27.4% |
| Dec 2019 | $59.29M | +33.2% | 98.5% | -116.5% | -112.8% |
| Dec 2018 | $44.51M | +892.6% | 99.4% | -163.3% | -158.3% |
| Dec 2017 | $4.48M | -78.0% | 100.0% | -1775.6% | -1755.7% |
| Dec 2016 | $20.38M | N/A | 100.0% | -342.2% | -340.0% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 1999.7% from the year before. In the quarter ended Sep 2026, net income fell 52.7% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $294.28M | $179.28M | $116.88M | $120.24M | $149.24M | $108.62M | $59.29M | $44.51M | $4.48M | $20.38M |
| Cost of revenue | $19.62M | $18.65M | $7.11M | $1.75M | $1.08M | $895.00K | $906.00K | $287.00K | $0 | $0 |
| Gross profit | $274.66M | $160.63M | $109.77M | $118.49M | $148.15M | $107.73M | $58.38M | $44.22M | $4.48M | $20.38M |
| Research and development | $33.30M | $23.38M | $24.52M | $60.27M | $65.24M | $60.10M | $52.88M | $46.90M | $46.27M | $63.45M |
| Operating income | $125.47M | $24.19M | -$20.49M | -$55.55M | -$12.50M | -$28.97M | -$69.09M | -$72.68M | -$79.62M | -$69.74M |
| Net income | $367.02M | $17.48M | -$25.09M | -$58.57M | -$17.91M | -$29.74M | -$66.89M | -$70.48M | -$78.72M | -$69.30M |
| EBITDA | $126.73M | $25.71M | -$19.73M | -$54.62M | -$11.05M | -$28.39M | N/A | N/A | -$79.50M | -$68.69M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $80.89M | $78.70M | $58.82M | $69.80M | $69.46M | $101.69M | $53.33M | $57.60M | $55.31M | $36.84M | $29.53M | $35.79M |
| Gross profit | $70.11M | $70.18M | $54.21M | $63.85M | $64.71M | $97.18M | $48.92M | $51.81M | $47.28M | $34.03M | $27.51M | $32.00M |
| Operating income | $17.11M | $23.57M | $11.88M | $23.17M | $28.42M | $61.10M | $12.77M | $16.66M | $14.06M | $447.00K | -$6.97M | $1.97M |
| Net income | $13.19M | $17.29M | $8.65M | $268.06M | $27.90M | $59.61M | $11.45M | $14.34M | $12.42M | -$1.03M | -$8.25M | $737.00K |
Balance Sheet
As of Dec 2025, total debt of $52.29M exceeded cash and equivalents by $11.71M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $513.59M | $163.98M | $117.22M | $134.28M | $167.33M | $110.38M | $147.57M | $139.11M | $119.11M | $78.13M |
| Current assets | $240.17M | $135.10M | $99.27M | $115.90M | $154.47M | $88.98M | $119.00M | $136.99M | $117.43M | $76.21M |
| Cash and equivalents | $40.58M | $56.75M | $32.79M | $24.46M | $18.89M | $30.37M | $22.52M | $76.32M | $38.29M | $17.63M |
| Total liabilities | $122.11M | $160.69M | $145.87M | $147.90M | $136.95M | $76.35M | $93.75M | $29.23M | $18.46M | $23.11M |
| Short-term debt | $29.81M | $7.27M | $7.23M | $0 | $9.89M | $8.62M | $7.27M | N/A | $284.00K | $3.22M |
| Long-term debt | $22.48M | $52.41M | $52.37M | $39.45M | $19.91M | $19.82M | $9.81M | N/A | $0 | $0 |
| Shareholder equity | $391.48M | $3.29M | -$28.64M | -$13.62M | $30.37M | $34.03M | $53.81M | $109.88M | $100.65M | $55.03M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $523.88M | $521.07M | $504.61M | $513.59M | $242.53M | $206.74M | $175.97M | $163.98M | $139.42M | $128.41M | $126.52M | $117.22M |
| Total liabilities | $78.77M | $95.64M | $104.71M | $122.11M | $124.92M | $124.80M | $157.41M | $160.69M | $154.06M | $158.32M | $158.19M | $145.87M |
| Cash and equivalents | $46.65M | $60.82M | $24.41M | $40.58M | $48.53M | $53.41M | $45.73M | $56.75M | $51.69M | $36.05M | $25.57M | $32.79M |
| Shareholder equity | $445.11M | $425.42M | $399.90M | $391.48M | $117.61M | $81.93M | $18.57M | $3.29M | -$14.64M | -$29.91M | -$31.67M | -$28.64M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 100.0% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $75.66M | $31.47M | -$5.74M | -$73.76M | $5.88M | -$52.19M | -$41.51M | -$58.83M | -$77.56M | -$75.89M |
| Capital expenditures | $0 | $36.00K | $0 | $450.00K | $627.00K | $1.26M | $1.46M | $1.11M | $164.00K | $804.00K |
| Free cash flow | $75.66M | $31.43M | -$5.74M | -$74.21M | $5.25M | -$53.45M | -$42.97M | -$59.93M | -$77.72M | -$76.69M |
| Investing cash flow | -$92.36M | $4.13M | -$4.30M | $72.78M | -$80.04M | $47.47M | -$23.66M | $24.96M | -$19.47M | $24.88M |
| Financing cash flow | $601.00K | -$11.64M | $18.37M | $6.55M | $62.67M | $12.57M | $11.37M | $71.89M | $117.69M | $25.18M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $34.56M | $30.65M | $2.73M | $21.98M | $24.03M | $30.54M | -$893.00K | $14.50M | $21.68M | $302.00K | -$5.01M | -$6.24M |
| Capital expenditures | N/A | N/A | $0 | $12.00K | $12.00K | $0 | $0 | $26.00K | $10.00K | $222.00K | $138.00K | $110.00K |
| Free cash flow | N/A | N/A | $2.73M | $21.97M | $24.02M | $30.54M | -$893.00K | $14.48M | $21.67M | $80.00K | -$5.15M | -$6.35M |
Frequently Asked Questions About RIGL
What is Rigel Pharmaceuticals' annual revenue?
Rigel Pharmaceuticals reported revenue of $294.28M for the fiscal year ended Dec 31, 2025.
How fast is Rigel Pharmaceuticals' revenue growing?
Revenue was up 64.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 34.8%.
Is Rigel Pharmaceuticals profitable?
Yes. Rigel Pharmaceuticals reported net income of $367.02M for the fiscal year ended Dec 31, 2025, with a net margin of 124.7%.
How much free cash flow does RIGL generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $75.66M minus capital expenditures of $0 produced free cash flow of $75.66M.
How much debt does Rigel Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $22.48M, short-term debt of $29.81M and cash and equivalents of $40.58M.
RIGL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors